公开(公告)号：US20240335489A1

公开(公告)日：2024-10-10

申请号：US18751599

申请日：2024-06-24

申请人： Baylor College of Medicine ,  United States Government as Represented by the Department of Veterans Affairs

发明人： Anthony Maresso ,  Robert Ramig ,  Sabrina Green ,  Austen Terwilliger ,  Keiko Salazar ,  Justin R. Clark ,  Barbara Trautner

IPC分类号： A61K35/76 ,  A61P31/04 ,  C12N7/00

CPC分类号： A61K35/76 ,  A61P31/04 ,  C12N7/00 ,  C12N2795/10132 ,  C12N2795/10171 ,  C12N2795/10232 ,  C12N2795/10271

摘要： Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

公开(公告)号：US20230174954A1

公开(公告)日：2023-06-08

申请号：US17917543

申请日：2021-04-27

申请人： Armata Pharmaceuticals, Inc.

发明人： Sébastien LEMIRE ,  Stacey Lynn KOLAR ,  Brian Clarke VARNUM

IPC分类号： C12N7/00 ,  A61K35/76 ,  A61P31/04 ,  A61K45/06

CPC分类号： C12N7/00 ,  A61K35/76 ,  A61P31/04 ,  A61K45/06 ,  C12N2795/10121 ,  C12N2795/10132 ,  C12N2795/10171 ,  C12N2795/10221 ,  C12N2795/10232 ,  C12N2795/10271

摘要： The present disclosure relates to bacteriophage and compositions capable of infecting and killing Pseudomonas, and use of the same for treating Pseudomonas, e.g. Pseudomonas aeruginosa, bacterial infections.

公开(公告)号：US20180369299A1

公开(公告)日：2018-12-27

申请号：US16064698

申请日：2016-11-10

申请人： INTRON BIOTECHNOLOGY, INC.

发明人： Seong Jun Yoon ,  Soo Youn Jun ,  An Sung Kwon ,  Soon Hye Hwang ,  Sang Hyeon Kang

IPC分类号： A61K35/76 ,  A23K20/195 ,  A61P31/04

CPC分类号： A61K35/76 ,  A23K20/195 ,  A23K50/80 ,  A61P31/04 ,  C12N7/00 ,  C12N2795/10221 ,  C12N2795/10232

摘要： The present invention relates to: Podoviridae bacteriophage Vib-PAP-1 (accession number KCTC 12817BP) which has the capability to specifically destroy Vibrio parahaemolyticus, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Vibrio parahaemolyticus infections, using a composition containing bacteriophage Vib-PAP-1 as an active ingredient.

公开(公告)号：US20160264941A1

公开(公告)日：2016-09-15

申请号：US15031763

申请日：2014-10-24

申请人： PHERECYDES PHARMA

发明人： Flavie POUILLOT ,  Hélène BLOIS

IPC分类号： C12N7/00 ,  A61K35/76 ,  C12Q1/18 ,  C07K14/005

CPC分类号： C12N7/00 ,  A61K35/76 ,  C07K14/005 ,  C12N2795/10121 ,  C12N2795/10122 ,  C12N2795/10132 ,  C12N2795/10171 ,  C12N2795/10221 ,  C12N2795/10222 ,  C12N2795/10232 ,  C12N2795/10271 ,  C12Q1/18

摘要： The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

摘要翻译： 本发明涉及噬菌体治疗。 更具体地，本发明涉及对绿脓假单胞菌菌株具有高特异性的新型噬菌体，其制造方法，其组分，包含其的组合物及其在噬菌体治疗中的用途。

公开(公告)号：US08043613B2

公开(公告)日：2011-10-25

申请号：US12378457

申请日：2009-02-12

申请人： Seongjun Yoon ,  Yunjaie Choi ,  Seyung Lee ,  Jeesoo Son ,  Sooyoun Jun ,  Sanghyeon Kang

发明人： Seongjun Yoon ,  Yunjaie Choi ,  Seyung Lee ,  Jeesoo Son ,  Sooyoun Jun ,  Sanghyeon Kang

IPC分类号： A01N63/00

CPC分类号： A61K35/76 ,  C12N7/00 ,  C12N2795/10232

摘要： The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.

摘要翻译： 本发明涉及一种新型噬菌体，更确切地说，具有针对人和动物感染性疾病引起的金黄色葡萄球菌特异性杀伤活性的波形病毒噬菌体，用于预防和治疗由金黄色葡萄球菌引起的疾病的药物组合物， 含有噬菌体作为活性成分的抗生素和消毒剂。

公开(公告)号：US20100209349A1

公开(公告)日：2010-08-19

申请号：US12579242

申请日：2009-10-14

申请人： Yun-Jeong Heo ,  Yu-Rim Lee ,  Hyun-Hee Jung ,  You-Hee Cho

发明人： Yun-Jeong Heo ,  Yu-Rim Lee ,  Hyun-Hee Jung ,  You-Hee Cho

IPC分类号： A61K49/00 ,  C12N7/00 ,  A61K35/76 ,  A61P31/04

CPC分类号： C12Q1/18 ,  A61K35/76 ,  C12N2795/10232

摘要： This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP (Restriction fragment length polymorphism) DNA profile substantially equivalent to the bacteriophage MPK6. The present invention provides a bacteriophage MPK6 or a progeny bacteriophage thereof capable of treating a Pseudomonas aeruginosa infection disease, and suggests an anti-bacterial activity of MPK6 and its progeny bacteriophage using a mammalian and non-mammalian infection model. According to the present invention, the present bacteriophage MPK6 or progeny bacteriophage thereof represents very effective efficacy on treatment of P. aeruginosa-induced peritonitis-sepsis.

摘要翻译： 本发明涉及具有对绿脓假单胞菌具有裂解活性的噬菌体MPK6（保藏号：KCCM 11044P），或其具有与噬菌体MPK6基本相同的RFLP（限制性片段长度多态性）DNA图谱的后代噬菌体。 本发明提供能够治疗铜绿假单胞菌感染疾病的噬菌体MPK6或其后代噬菌体，并且使用哺乳动物和非哺乳动物感染模型提示MPK6及其后代噬菌体的​​抗细菌活性。 根据本发明，本发明的噬菌体MPK6或其后代噬菌体对治疗铜绿假单胞菌诱导的腹膜炎败血症具有非常有效的疗效。

公开(公告)号：US20240182869A1

公开(公告)日：2024-06-06

申请号：US18285729

申请日：2022-04-08

申请人： APARON LTD.

发明人： Joseph Charles Samuel BROWN ,  Joseph Riziero EDWARDS ,  Sammy James KAY ,  Ellen Olivia DENNESS ,  Christopher Jeremy STANFORD

IPC分类号： C12N7/00 ,  A23K10/16 ,  A61K35/76 ,  A61P31/04 ,  C12Q1/04

CPC分类号： C12N7/00 ,  A23K10/16 ,  A61K35/76 ,  A61P31/04 ,  C12Q1/04 ,  C12N2795/10121 ,  C12N2795/10132 ,  C12N2795/10221 ,  C12N2795/10232 ,  C12N2795/10321 ,  C12N2795/10332

摘要： The invention relates to the field of phage therapy. It particularly relates to providing phages, phage-based compositions and methods for treating or preventing bacterial infections, particularly C. perfringens, in animals, including humans, aquaculture and livestock. The invention also relates to uses of the compositions as a feedstuff and as a biological decontaminator in feed and food products for human and animal consumption.

公开(公告)号：US10077431B2

公开(公告)日：2018-09-18

申请号：US15031763

申请日：2014-10-24

申请人： PHERECYDES PHARMA

发明人： Flavie Pouillot ,  Hélène Blois

IPC分类号： A01N63/00 ,  A61K39/12 ,  A61K39/00 ,  A61K39/285 ,  A61K39/275 ,  C12N7/00 ,  A61K35/76 ,  C07K14/005 ,  C12Q1/18

CPC分类号： C12N7/00 ,  A61K35/76 ,  C07K14/005 ,  C12N2795/10121 ,  C12N2795/10122 ,  C12N2795/10132 ,  C12N2795/10171 ,  C12N2795/10221 ,  C12N2795/10222 ,  C12N2795/10232 ,  C12N2795/10271 ,  C12Q1/18

摘要： The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

公开(公告)号：US09457132B2

公开(公告)日：2016-10-04

申请号：US14119716

申请日：2012-06-28

申请人： Rodney Martin Donlan ,  Susan Marie Lehman ,  Andres J. Garcia

发明人： Rodney Martin Donlan ,  Susan Marie Lehman ,  Andres J. Garcia

IPC分类号： A61L29/10 ,  A01N63/00 ,  A61L27/34 ,  A61L27/52 ,  A61L27/54 ,  A61L29/08 ,  A61L29/14 ,  A61L31/10 ,  A61L31/14 ,  A61L31/16 ,  A61L15/60 ,  A61L15/36 ,  A61L27/36 ,  A61L29/16 ,  A61L15/44 ,  A61K35/76 ,  A61M25/00

CPC分类号： A61L29/106 ,  A01N63/00 ,  A61K35/76 ,  A61L15/36 ,  A61L15/44 ,  A61L15/60 ,  A61L27/34 ,  A61L27/3637 ,  A61L27/52 ,  A61L27/54 ,  A61L29/08 ,  A61L29/085 ,  A61L29/145 ,  A61L29/16 ,  A61L31/10 ,  A61L31/145 ,  A61L31/16 ,  A61L2300/102 ,  A61L2300/104 ,  A61L2300/404 ,  A61L2300/406 ,  A61L2300/606 ,  A61M2025/0056 ,  C12N2795/10132 ,  C12N2795/10232 ,  C12N2795/10332 ,  A01N25/10 ,  A01N25/34

摘要： Medical devices that are resistant to biofilm development and methods of the manufacture of biofilm resistant medical devices are provided. One or more bacteriophages are tethered to the surface of a medical device or a hydrogei-type coating on the surface of the device by covalent bonding while maintaining bacteriophage infective or lytic activity. The presence of the bacteriophages on a medical device, such as an indwelling medical device, prevents biofilm formation or reduces existing biofilm formation on the surface of the device when in use. These devices address the long felt need for biofilm resistant devices that increase safety and reduce complications normally associated with prior indwelling or other medical devices.

摘要翻译： 提供了抗生物膜发展的医疗装置和制造生物膜抗性医疗装置的方法。 一个或多个噬菌体通过共价键连接到医疗装置的表面或器件表面上的水i型涂层，同时保持噬菌体感染或溶解活性。 在医疗装置（例如留置医疗装置）上的噬菌体的存在防止生物膜形成或在使用时减少在装置表面上的现有生物膜形成。 这些装置解决了对生物膜抗性装置的长期需求，其增加安全性并减少通常与先前留置的其他医疗装置相关联的并发症。

公开(公告)号：US20160244745A1

公开(公告)日：2016-08-25

申请号：US15032753

申请日：2014-10-31

申请人： REGENTS OF THE UNIVERSITY OF MINNESOTA

发明人： Benjamin Joseph Hackel ,  Max Anthony Kruziki ,  Sumit Bhatnagar ,  Hong Zhou

IPC分类号： C12N15/10 ,  C07K14/005 ,  C12N7/00

CPC分类号： C12N15/1044 ,  A61K38/00 ,  A61K38/162 ,  C07K14/005 ,  C12N7/00 ,  C12N2795/10222 ,  C12N2795/10232

摘要： This disclosure describes non-naturally occurring protein scaffolds and methods of making and using the protein scaffolds. In one aspect, therefore, this disclosure describes a non-naturally occurring protein scaffold that includes a plurality of structural domains and a plurality of loop regions that include an amino acid sequence that varies from a naturally-occurring loop region by at least one amino acid deletion, substitution, or addition. Generally, the structural domain or domains can include at least one β structure and/or at least one a helix.

摘要翻译： 本公开描述了非天然存在的蛋白质支架和制备和使用蛋白质支架的方法。 因此，一方面，本公开内容描述了非天然存在的蛋白质支架，其包括多个结构域和多个环区，其包含从天然存在的环区与至少一个氨基酸变化的氨基酸序列 删除，替换或添加。 通常，结构域或结构域可以包括至少一个β结构和/或至少一个螺旋。